Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status
In this subgroup analysis of COSMIC-311, cabozantinib improved PFS and ORR versus placebo irrespective of <i>BRAF</i> mutation status. Thus, cabozantinib is an efficacious treatment option with a manageable safety profile for previously treated patients with RAIR-DTC, including those with <i>BRAF</i> <sup>V600E</sup>.
Authors
- Marcia S. Brose (ORCID: https://orcid.org/0000-0001-7096-4057)
- N. Berry
- Svetlana Andrianova
- Xiang Guo (ORCID: https://orcid.org/0009-0005-9940-9037)
- B. Robinson
- Nuttapong Ngamphaiboon (ORCID: https://orcid.org/0000-0002-6535-6345)
- Fernanda Vaisman (ORCID: https://orcid.org/0000-0002-6835-7108)
- Denise Williamson
- Cindy Lin (ORCID: https://orcid.org/0000-0003-2379-7369)
- Andrew D. Simmons (ORCID: https://orcid.org/0000-0001-6075-0549)
- B. Keam
- Ana Oliveira Hoff
- Steven I. Sherman
- Erika Hitre
- Jolanta Krajewska
- Jaume Capdevila
- Daniel W. Bowles
Institutions
- Hebron University (PS)
- The University of Texas MD Anderson Cancer Center (US)
- Exelixis (United States) (US)
- Mahidol University (TH)
- Royal North Shore Hospital (AU)
- Seoul National University Hospital (KR)
- Instituto do Câncer do Estado de São Paulo (BR)
- Sidney Kimmel Cancer Center (US)
- Instituto Nacional de Cancerología (CO)
- National Institute of Oncology (HU)
- National Taiwan University Hospital (TW)
- Országos Pszichiátriai és Neurológiai Intézet (HU)
- Ramathibodi Hospital (TH)
- Instituto Nacional de Câncer - INCA (BR)
- Instituto Nacional del Cáncer (CL)
- Instituto Nacional de Cancerología (MX)
- Sidney Kimmel Comprehensive Cancer Center (US)
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-03-04
- DOI
- https://doi.org/10.3389/fonc.2026.1748566
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Exelixis